|
1
|
Small W Jr, Bacon MA, Bajaj A, Chuang LT,
Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR,
Viswanathan AN, et al: Cervical cancer: A global health crisis.
Cancer. 123:2404–2412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wentzensen N, Schiffman M, Palmer T and
Arbyn M: Triage of HPV positive women in cervical cancer screening.
J Clin Virol. 76 (Suppl 1):S49–S55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drews CM, Case S and Vande Pol SB: E6
proteins from high-risk HPV, low-risk HPV, and animal
papillomaviruses activate the Wnt/β-catenin pathway through
E6AP-dependent degradation of NHERF1. PLoS Pathog. 15:e10075752019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Basukala O, Mittal S, Massimi P, Bestagno
M and Banks L: The HPV-18 E7 CKII phospho acceptor site is required
for maintaining the transformed phenotype of cervical
tumour-derived cells. PLoS Pathog. 15:e10077692019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM,
Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, et al:
Cervical cancer, version 2.2015. J Natl Compr Canc Netw.
13:395–404; quiz 404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, He M, Chao A, Engelgau MM, Saraiya
M and Wang L and Wang L: Cervical cancer screening among adult
women in China, 2010. Oncologist. 20:627–634. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ibeanu OA: Molecular pathogenesis of
cervical cancer. Cancer Biol Ther. 11:295–306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crafton SM and Salani R: Beyond
chemotherapy: An overview and review of targeted therapy in
cervical cancer. Clin Ther. 38:449–458. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chandra Gupta S and Nandan Tripathi Y:
Potential of long non-coding RNAs in cancer patients: From
biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui Y, Fan Y, Zhao G, Zhang Q, Bao Y, Cui
Y, Ye Z, Chen G, Piao X, Guo F, et al: Novel lncRNA PSMG3 AS1
functions as a miR 143 3p sponge to increase the proliferation and
migration of breast cancer cells. Oncol Rep. 43:229–239.
2020.PubMed/NCBI
|
|
13
|
Wong CK, Gromisch C, Ozturk S, Papageorgis
P, Abdolmaleky HM, Reinhard BM, Thiagalingam A and Thiagalingam S:
MicroRNA-4417 is a tumor suppressor and prognostic biomarker for
triple-negative breast cancer. Cancer Biol Ther. 20:1113–1120.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu CS, Spirtos A, Khulpateea BR and Lea
JS: AJCC versus FIGO staging of cervical cancer to predict disease
severity. Gynecol Oncol. 149:1552018. View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) μethod. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mann M, Wright PR and Backofen R: IntaRNA
2.0: Enhanced and customizable prediction of RNA-RNA interactions.
Nucleic Acids Res. 45:W435–W439. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song L, Zhang W, Chang Z, Pan Y, Zong H,
Fan Q and Wang L: miR-4417 targets tripartite motif-containing 35
(TRIM35) and regulates pyruvate kinase muscle 2 (PKM2)
phosphorylation to promote proliferation and suppress apoptosis in
hepatocellular carcinoma cells. Med Sci Monit. 23:1741–1750. 2017.
View Article : Google Scholar : PubMed/NCBI
|
